WebMar 4, 2024 · Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2 study assessed fedratinib in patients with intermediate- or high-risk myelofibrosis (MF) who were resistant or intolerant to prior ruxolitinib per investigator assessment. Patients received fedratinib 400 mg/day in 28-day cycles. WebINREBIC ® (fedratinib) is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential …
Fedratinib in myelofibrosis - American Society of …
WebFedratinib hydrochloride is approved for use in adults to treat: Myelofibrosis (a bone marrow disease) that is intermediate-2 risk or high risk, including the following types: Primary … WebDec 11, 2024 · Inrebic ® (fedratinib) is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). Inrebic is a JAK2-selective inhibitor with higher potency for JAK2 over family members JAK1, JAK3 and TYK2. Abnormal activation of JAK2 is associated with ... third base braves
Fedratinib Oral: Uses, Side Effects, Interactions, Pictures ... - WebMD
WebFeb 1, 2024 · Fedratinib is used to treat intermediate-2 or high-risk myelofibrosis, including primary or secondary (post-polycythemia vera and post-essential thrombocythemia) … WebJan 14, 2024 · Uses for fedratinib. Fedratinib is used to treat intermediate-2 or high-risk myelofibrosis, including primary or secondary (post-polycythemia vera and post-essential … WebFedratinib, an oral Janus kinase-2 (JAK2) inhibitor, reduces splenomegaly and improves symptom burden in patients with myelofibrosis. Regulatory approval of fedratinib 400 … third base carlton mn